BoobyBiome, a start-up innovating the realm of infant health, is spearheading efforts to redefine neonatal care through a deep understanding of the gut microbiome. Founded by Lydia, Sioned, and Tara, they are dedicated to leveraging cutting-edge science to optimise infant health outcomes, particularly focusing on premature infants.
Joanna Myslinska
December 13, 2024
Companies looking to get innovative biology to patients around the world need to be aware that it takes a 360-degree view of the intellectual property requirements, and in the case of CRISPR this landscape is becoming more and more convoluted, with companies scrambling to renegotiate licensing laws for GMOs to use in research and industry. Taken together, this points towards an opportunity for Forge Genetics to position themselves perfectly, to create a novel, gold-standard gene-editing technology, supporting innovation throughout the global biotechnology industry.
Aonghus Topham
December 13, 2024
The rising tide of antimicrobial resistance (AMR) is recognised as one of the major hurdles of the 21st century, being predicted to cause more deaths worldwide than cancer within the next 25 years [5]. Our overuse of antibiotic agents is driving the evolution of novel antimicrobial-resistant bacterial strains across both agricultural and healthcare sectors. Humanity is fighting a losing battle against billions of years of bacterial evolution. To keep in this fight, we need to come up with more innovative solutions within the field of antimicrobial biotechnology.
December 13, 2024
PentaBind, a biotech start-up from London, aims to drug the undruggable, targeting diseases that have long been considered beyond the reach of conventional drug discovery methods. Recognising that only 15% of the human proteome has been effectively targeted by existing drugs [2], they are pioneering a novel therapeutic approach that combines the high specificity of aptamers with the power of artificial intelligence (AI).
December 13, 2024
In the quest to revolutionise cancer diagnosis, BioMavericks emerged amidst the COVID-19 crisis, recognizing a crucial gap in advanced sequencing methods for cancer detection. Their ground-breaking in vitro diagnostic tool, fuelled by proprietary biomarkers, with a sensitivity and specificity of over 97% promises exceptional accuracy in detecting prevalent cancers.
December 13, 2024
Anticoagulants are an essential class of medications that are primarily used to prevent thrombotic events in individuals classified as at high risk of blood clot formation. Several risk factors can increase an individual’s risk of developing a blood clot, including a previous history of blood clots (venous thromboembolism), a previous history of myocardial infarction or stroke, cardiac valve replacement, genetic clotting disorders and comorbidities such as atrial fibrillation.
Matthew McCann
December 13, 2024
Sign up for our monthly newsletter of upcoming events, recently published insights and SEC updates.
